Nobuyuki Amano - Concepedia

Author

Nobuyuki Amano

Takeda (Japan)

Also Known As

Amano Nobuyuki, Amano, N., Amano, Nobuyuki, N. Amano, NOBUYUKI AMANO, Nobuyuki AMANO, Nobuyuki Amano

Publications

Citations

H-Index

Concepts

All Affiliations

Takeda (Japan)Yamaguchi Prefecture Central Hospital Toho University Hyogo Social Welfare Corporation Nagoya University

About

Nobuyuki Amano is an author at Takeda (Japan) specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	17	382
2	Engineering	3	3	110
3	Health Sciences	3	3	81
4	Natural Sciences	3	3	71
5	Social Sciences	1	1	12

Nobuyuki Amano

Publications

894

Citations

H-Index

Page 1

	Year	Citations
Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations Masatoshi Karashima, Noriyasu Sano, S. Yamamoto, European Journal of Pharmaceutics and Biopharmaceutics Materials ScienceEngineeringEnhanced Pulmonary AbsorptionBiomedical EngineeringSoluble Itraconazole	2017	60
Design, synthesis, and structure–activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors Makoto Kamata, Asato Kina, Masaaki Funata, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryNovel Spiro-piperidinesBiochemistryMedicineNatural Sciences	2012	49
Quantitative Investigation of the Impact of P-Glycoprotein Inhibition on Drug Transport across Blood-Brain Barrier in Rats Hiroshi Sugimoto, Hideki Hirabayashi, Yoshiaki Kimura, Drug Metabolism and Disposition	2010	49
Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver Maki Miyamoto, Shinji Iwasaki, Ikumi Chisaki, Xenobiotica	2016	46
Establishment of In Vitro P-Glycoprotein Inhibition Assay and Its Exclusion Criteria to Assess the Risk Of Drug–Drug Interaction at the Drug Discovery Stage Hiroshi Sugimoto, Shin-ichi Matsumoto, Miho Tachibana, Journal of Pharmaceutical Sciences Drug InteractionsDrug AnalysisDrug–drug InteractionDrug TargetBiochemistry	2011	43
Symmetrical approach of spiro-pyrazolidinediones as acetyl-CoA carboxylase inhibitors Makoto Kamata, Asato Kina, Michiko Tawada, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicinePharmacological AgentSymmetrical ApproachPharmacotherapy	2012	41
Asymmetric Intestinal First-Pass Metabolism Causes Minimal Oral Bioavailability of Midazolam in Cynomolgus Monkey Tomohiro Nishimura, Nobuyuki Amano, Yoshiyuki Kubo, Drug Metabolism and Disposition	2007	40
Effects of Dietary Fructose or Glucose on Triglyceride Production and Lipogenic Enzyme Activities in the Liver of Wistar Fatty Rats, an Animal Model of NIDDM. Tsutomu Kazumi, Hiroyuki Odaka, Toshiki Hozumi, Endocrine Journal NutritionWistar Lean RatsFatty Liver DiseaseInsulin SignalingObesity	1997	38
In Vivo Biliary Clearance Should Be Predicted by Intrinsic Biliary Clearance in Sandwich-Cultured Hepatocytes Masanori Nakakariya, Midori Ono, Nobuyuki Amano, Drug Metabolism and Disposition	2011	38
VLDL Triglyceride Kinetics in Wistar Fatty Rats, An Animal Model of NIDDM: Effects of Dietary Fructose Alone or in Combination With Pioglitazone Tsutomu Kazumi, Tsutomu Hirano, Hiroyuki Odaka, Diabetes	1996	37

Page 1